Mark R. Busch

Represented Exact Sciences Corporation (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, in connection with a number of underwritten public offerings of common stock and convertible notes with total gross proceeds exceeding US$3 billion, and a number of acquisitions with aggregate purchase prices exceeding US$3 billion.

Represented Exact Sciences Corporation (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, in connection with issuance of US$500 million aggregate principal amount of a new series of 2.00% Convertible Senior Notes due 2030 in exchange for (i) US$183.7 million aggregate principal amount of existing 2027 Notes, (ii) US$200.9 million aggregate principal amount of existing 2028 Notes, and (iii) approximately US$138 million in cash.

Represented Exact Sciences Corporation (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, in acquiring all of the outstanding equity interests of PreventionGenetics, a Wisconsin-based genetic testing laboratory.

Represented Movano Inc. (NASDAQ: MOVE), a health technology company and maker of the Evie Ring, in connection with its initial public offering of shares of common stock on NASDAQ and multiple follow-on offerings, including underwritten public offerings and at-the-market financing transactions.

Represented Movano Health (NASDAQ: MOVE), a health technology company, with a $24.1 million private placement of common stock and warrants to a select group of investors that includes a tier-one multibillion-dollar medical device company, institutional and accredited investors, and members of the company's management team and board of directors.

Represented Movano Inc. (NASDAQ: MOVE), a health technology company and maker of the Evie Ring, with respect to an underwritten public offering of common stock with The Benchmark Company, LLC, a full-service investment banking firm, as the underwriter.

Represented MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, in its initial public offering and listing on NASDAQ and multiple follow-on offerings, including underwritten public offerings and at-the-market financing transactions.

Represented Cue Biopharma, Inc. (NASDAQ: CUE), an immunotherapy company, in connection with its initial public offering and listing on NASDAQ, and several follow-on at-the-market financing transactions.

Represented GQG Partners, Inc. (ASX: GQG), a global investment boutique focused on managing active equity portfolios, with respect to securities and corporate governance matters.

Represented CodeLogic, Inc., a software as a service provider, in connection with a number of private placement transactions.

Represented CLOCworks, Inc., a software as a service provider, in connection with a number of private placement transactions.

Represented a manufacturer of healthcare products with respect to a number of acquisitions.

Represented Energous Corporation (NASDAQ: WATT), a developer of wireless charging technology, in connection with its initial public offering and listing on NASDAQ, and several follow-on secondary financing transactions.

Represented EnSync, Inc. (NYSE American: ESNC), an alternative energy company, in connection with several public and private offerings of shares of common stock, convertible preferred stock, warrants, and convertible notes.

Represented ENDRA Life Sciences Inc. (NASDAQ NDRA), an ultrasound technology company, in connection with its initial public offering and listing on NASDAQ and multiple follow-on offerings, including bridge note financings, underwritten public offerings, and at-the-market financing transactions.